Loading organizations...
§ Public · Cambridge, MA, USA
clinical-stage biotech company developing therapies for oncology, hematology, immunology, inflammation, and neuroscience.
Centessa Pharmaceuticals has raised $250.0M across 1 funding round.
Key people at Centessa Pharmaceuticals.
Centessa Pharmaceuticals has raised $250.0M in total across 1 funding round.
Centessa Pharmaceuticals is a clinical-stage biotechnology company developing innovative therapies across oncology, hematology, immunology, inflammation, and neuroscience from its dual headquarters in Cambridge, Massachusetts, and Cambridge, United Kingdom. The enterprise operates through a unique structural model that initially merged 10 early-stage biotech firms into autonomous subsidiaries supported by centralized capital and administrative resources. To finance its diverse clinical pipeline, the firm secured a $250 million Series A funding round before completing a $330 million initial public offering in 2021. The publicly traded entity advances multiple clinical programs through subsidiaries such as ApcinteX, which specifically develops treatments for patients with hemophilia. The broader organization is guided by notable industry figures, including chief scientific advisor Moncef Slaoui. Centessa Pharmaceuticals was founded in 2020 by the European life sciences venture capital firm Medicxi alongside co-founder Saurabh Saha.
Key people at Centessa Pharmaceuticals.
Centessa Pharmaceuticals has raised $250.0M in total across 1 funding round.
Centessa Pharmaceuticals's investors include General Atlantic, Vida Ventures, Janus Henderson Investors, Atlas Venture, Boxer Capital, BVF Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, LifeSci Venture Partners, Logos Capital, Samsara BioCapital.
Centessa Pharmaceuticals has raised $250.0M across 1 funding round. Most recently, it raised $250.0M Series A in February 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2021 | $250M Series A | General Atlantic, Vida Ventures, Janus Henderson Investors | Atlas Venture, Boxer Capital, BVF Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Lifesci Venture Partners, Logos Capital, Samsara BioCapital, T. Rowe Price Associates, Venrock, Wellington Management | Announced |
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company, not a technology company in the traditional software or hardware sense, focused on discovering and developing transformational medicines for patients with sleep-wake disorders, neurological conditions, and cancer.[1][2][3] It builds potential best-in-class orexin receptor 2 (OX2R) agonists—orally administered drugs targeting narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), impaired attention, cognitive deficits, fatigue, and other neuropsychiatric symptoms—alongside an early-stage immuno-oncology program using the LockBody® technology platform.[2] Serving patients with unmet needs in neuroscience and oncology, Centessa addresses critical gaps in treatments for excessive daytime sleepiness and solid tumors by leveraging structure-based drug design and antibody engineering innovations.[1][2] Recent growth includes a CEO transition to expand orexin leadership into multiple neuroscience indications, a $250 million public offering, and headquarters completion in Boston.[1][3]
Centessa Pharmaceuticals emerged as a next-generation biotech with a research and development innovation engine, though specific founding year and founders are not detailed in available sources.[3][4] Key leaders include Dr. Mario Alberto Accardi, President of the Orexin Program and a biomedical engineer who pioneered structure-based drug design to rethink sleep-wake disorder treatments, and Dr. William Finlay, President of the LockBody Program and an antibody engineering expert who developed the LockBody® platform for immuno-oncology.[2] The company's idea stemmed from identifying unique medical needs: Accardi disrupted conventional approaches to orexin agonists for neurological conditions, while Finlay aimed to redefine cancer treatments, leading to a portfolio of innovative assets and data-driven R&D.[2][4] Early traction is marked by advancing clinical-stage programs and recent financing milestones like the $250 million offering.[1]
Centessa rides the trend of precision neuroscience and immuno-oncology, where structure-based drug design and antibody platforms enable targeted therapies for underserved conditions like narcolepsy and cancer, amid rising demand for oral treatments over invasives like hypocretin replacement.[2] Timing aligns with growing recognition of orexin pathways in sleep-wake regulation and neurodegeneration, fueled by market forces such as aging populations, post-pandemic sleep disorder surges, and immuno-oncology breakthroughs.[1][2] By influencing the ecosystem through its innovation engine and programs like OX2R agonists and LockBody®, Centessa contributes to biotech's shift toward multimodal neuroscience solutions, potentially setting standards for oral agonists in neuropsychiatric care.[2][4]
Centessa is poised to advance its orexin program into clinical trials across neuroscience indications, leveraging recent $250M funding and leadership changes for pipeline expansion, while maturing LockBody® toward oncology proofs-of-concept.[1][2] Trends like AI-driven drug design and personalized neurology will shape its path, amplifying structure-based innovations amid biotech's focus on brain health and cancer. Its influence may evolve by pioneering oral orexin therapies, transforming patient outcomes in sleep and neuro disorders, and tying back to its mission of delivering impactful, best-in-class medicines.[1][2][4]
